Unique ID issued by UMIN | UMIN000022003 |
---|---|
Receipt number | R000023199 |
Scientific Title | A study on the effect of "Sasahealth" used for oral mucositis associated with the anti-cancer agent administration |
Date of disclosure of the study information | 2016/04/20 |
Last modified on | 2017/08/30 18:28:05 |
A study on the effect of "Sasahealth" used for oral mucositis associated with the anti-cancer agent administration
A study on the effect of "Sasahealth" used for oral mucositis associated with the anti-cancer agent administration
A study on the effect of "Sasahealth" used for oral mucositis associated with the anti-cancer agent administration
A study on the effect of "Sasahealth" used for oral mucositis associated with the anti-cancer agent administration
Japan |
Oral mucositis which was developed by the side effects of anti-cancer drug therapy for lung cancer
Pneumology | Dental medicine |
Malignancy
NO
Collecting basic data on the effect of "Sasahealth" for oral mucositis that occurs as an adverse event of the anti-cancer agent administration
Safety,Efficacy
Exploratory
Explanatory
Not applicable
1.The evaluation of oral mucositis after "Sasahealth" p.o.
2.The searching for inflammatory markers (IL-6, IL-8, etc.)in the saliva after "Sasahealth" p.o.
1.Safety assessment(adverse event)
2.Diary described
3.Questionnaire survey
Interventional
Parallel
Non-randomized
Open -no one is blinded
Dose comparison
2
Treatment
Medicine |
Sasahealth 6.7mg gargled three times a day for 60 seconds before meals.
Sasahealth 6.7mg gargled three times a day for 60 seconds before meals.
20 | years-old | <= |
Not applicable |
Male and Female
1. Subjects are competent to consent, keep the rules of the study and are able to report self-condition.
2. Subjects who are judged eligible by the investigator in several series of medical check conducted prior to study.
3. Subjects who developed oral mucositis within one month or during chemotherapy newly.
4. Subjects who performed chemotherapy or planed to at department of Respiratory medicine in our clinic.
1. Subjects who have an inappropriate clinical history for efficacy and safety assessment in the study (such as drug poisoning, alcoholism, and the disease of heart, liver, kidney, lungs, eye, blood etc)
2.Any history for drug allergy
3. Subjects within three months after the participation to other clinical trials
4.Subjects who are inadequate for enrollment judged by the investigator.
10
1st name | |
Middle name | |
Last name | Norio HORIE |
Saitama Medical Center
Saitama Medical University
Department of Oral and MaxillofacialSurgery
1981 Kamoda, Kawagoe 350-8550 Saitama
049-228-3687
horien@saitama-med.ac.jp
1st name | |
Middle name | |
Last name | Norio HORIE |
Saitama Medical Center Saitama Medical University
Department of Oral and MaxillofacialSurgery
1981 Kamoda, Kawagoe 350-8550 Saitama
049-228-3687
horien@saitama-med.ac.jp
Saitama Medical Center Saitama Medical University. Department of Oral and MaxillofacialSurgery.
none
Self funding
Saitama Medical Center, Saitama Medical University, Department of Respiratory medicine
Saitama Medical Center, Saitama Medical University, Department of chemotherapy
NO
埼玉医科大学総合医療センター(埼玉県)
2016 | Year | 04 | Month | 20 | Day |
Unpublished
Open public recruiting
2015 | Year | 12 | Month | 24 | Day |
2015 | Year | 12 | Month | 24 | Day |
2016 | Year | 04 | Month | 20 | Day |
2017 | Year | 08 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023199